-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TD8tIB9bsSTXTbzYBVwmWjx1tld3skEGu0mySglmsE4bfttRyb3hcGLT04Uq2mR8
 w/pepiGd9oUasHLDS3+54g==

<SEC-DOCUMENT>0001193125-09-142811.txt : 20090701
<SEC-HEADER>0001193125-09-142811.hdr.sgml : 20090701
<ACCEPTANCE-DATETIME>20090701163257
ACCESSION NUMBER:		0001193125-09-142811
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090701
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090701
DATE AS OF CHANGE:		20090701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		09922941

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Date of Report (Date of earliest event reported): July&nbsp;1, 2009 (July 1, 2009) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200, Broomfield, CO 80021 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Section&nbsp;5 &#150; Corporate Governance and Management </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B>
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(b) On July&nbsp;1, 2009, ARCA biopharma, Inc., a Delaware corporation (the &#147;Company&#148;) announced that Richard Brewer was
resigning as the Company&#146;s Chief Executive Officer and that his employment with the Company would be ending effective as of July&nbsp;10, 2009. Effective July&nbsp;10, 2009, Mr.&nbsp;Brewer will assume the role of Chairman of the Board of
Directors of the Company. The press release is attached hereto as Exhibit&nbsp;99.1 and incorporated herein by reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) On
July&nbsp;1, 2009, the Company announced that effective July&nbsp;10, 2009 Michael R. Bristow will resign as Chairman of the Board and become President and Chief Executive Officer of the Company, a position Dr.&nbsp;Bristow previously held with the
Company prior to Mr. Brewer&#146;s appointment. Dr.&nbsp;Bristow will remain a member of the Board of Directors. The Company is not aware of any transaction requiring disclosure under Item&nbsp;404(a) of Regulation S-K other than previously
disclosed. The press release is attached hereto as Exhibit&nbsp;99.1 and incorporated herein by reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(e) Effective July&nbsp;10,
2009, the first sentence of Section&nbsp;3 of that certain Amended and Restated Employment Agreement dated June&nbsp;1, 2008 between Dr.&nbsp;Bristow and the Company will be amended to provide that he will be paid a reduced salary of $8,333.34 per
month in order to conserve the Company&#146;s available cash. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Amended and Restated Employment Agreement dated June&nbsp;1, 2008
between Mr. Brewer and the Company will terminate effective on July&nbsp;10, 2009. In order to conserve the Company&#146;s available cash, Mr. Brewer chose to forego any additional salary or cash severance payments under the terms of such agreement.
As a continuing director, Mr.&nbsp;Brewer will be entitled to receive an annual retainer fee of $30,000 per year and an annual grant of an additional 3,500 shares of the Company&#146;s common stock under the Amended and Restated ARCA biopharma, Inc.
2004 Equity Incentive Plan pursuant to the Company&#146;s existing non-employee director compensation plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Section&nbsp;9 &#150; Financial Statements
and Exhibits </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>9.01 Financial Statements and Exhibits. </B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>(d) Exhibits. </I>
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release, dated July 1, 2009, entitled &#147;ARCA biopharma Announces Changes to Management Team Reflecting Change in Commercial Strategy.&#148;</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dated: July&nbsp;1, 2009 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">(Registrant)
</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Kathryn E. Falberg</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Kathryn E. Falberg</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT FACE="Times New Roman" SIZE="2">Chief&nbsp;Financial&nbsp;Officer&nbsp;and&nbsp;Chief&nbsp;Operating&nbsp;Officer</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release, dated July 1, 2009, entitled &#147;ARCA biopharma Announces Changes to Management Team Reflecting Change in Commercial Strategy.&#148;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g27360g20j43.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Derek Cole
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com </U></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>ARCA BIOPHARMA ANNOUNCES CHANGES TO MANAGEMENT TEAM </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>REFLECTING CHANGE IN COMMERCIAL STRATEGY </B>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>Broomfield, CO, July 1, 2009</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for
heart failure and other cardiovascular diseases, today announced changes to its management team to reflect the Company&#146;s recent change in commercial strategy to seek alternatives for the potential commercialization of Gencaro. Richard B. Brewer
will assume the role of Chairman of the Board of Directors and resign as Chief Executive Officer. Michael R. Bristow, will become President and Chief Executive Officer, a position he previously held with ARCA prior to Mr.&nbsp;Brewer joining the
Company. Dr. Bristow will resign as Chairman but will remain a member of the Board of Directors. These changes will be effective on July&nbsp;10, 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">&#147;Today ARCA must balance its cash resources with the continued prosecution of the Gencaro New Drug Application,&#148; said Richard B. Brewer, incoming Chairman of the Board of Directors. &#147;These changes in management focus are
intended to allow exactly that to happen, while advancing the strategic interests of the stockholders.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;I look forward to Dick&#146;s continued
contributions to ARCA as Chairman of our Board of Directors,&#148; said Michael R. Bristow, incoming President and Chief Executive Officer of ARCA. &#147;His experience and expertise with cardiovascular therapeutics and the biotechnology industry in
general will be a great asset to the Company as we continue seeking regulatory approval of Gencaro.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman" SIZE="2">ARCA biopharma, Inc. is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company&#146;s
lead product candidate, Gencaro</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the
potential to be the first genetically-targeted heart failure treatment. The New Drug Application for approval of Gencaro for the indication of chronic heart failure, including the proposed brand name, was filed in September 2008. On May&nbsp;29,
2009, ARCA received a Complete Response letter from the FDA. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the
timing and outcome of regulatory review and approval of the Company&#146;s New Drug Application for Gencaro; the Company&#146;s ability to commercialize Gencaro, should it receive regulatory approval, and, the company&#146;s ability to fund future
operations. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many
factors, including, without limitation, the risks and uncertainties associated with: the company&#146;s financial resources and whether they will be sufficient to meet the company&#146;s business objectives and operational requirements; the
company&#146;s ability to complete a strategic transaction to support the potential commercialization of Gencaro, if approved and/or obtain additional financing; the timing and outcome of the FDA&#146;s review of the company&#146;s New Drug
Application for Gencaro, the company&#146;s ability to further identify, develop and achieve commercial success for products and technologies; drug discovery and the regulatory approval process; clinical development processes; relationships with
strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and, the impact of competitive products and technological changes. These and other factors are identified and
described in more detail in ARCA&#146;s filings with the SEC, including without limitation the company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2008, the company&#146;s quarterly report on Form 10-Q for the quarter
ended March&nbsp;31, 2009 and subsequent filings and press releases. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g27360g20j43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g27360g20j43.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1P#3`P$1``(1`0,1`?_$`,(````&`P$!````````
M```````&!P@)"@(#!00!`0$``0,%`0``````````````!P,&"`$"!`4)"A``
M``4#`P(#!0()"`H#`````0(#!`41!@<`$@@A$S$4"4%1(A4683)Q@9'10E(C
M)!>AL9(S@\,T"O#!<E,E)K9W.!EB5!@1``$#`P(#!`,-!@0'``````$``@,1
M!`4A!C$2!T%A(A-1@0AQD:&QX3)"4F)R(S,4P;+20Q4)\,)38X.S)&0E%A?_
MV@`,`P$``A$#$0`_`+='*GEG+8XF%\=XX%L:YTDR'G[@=)B[0M_S/[5-BR:'
M(9%Q)"W."ASGJ1$I@H`FZ!YY^UE[7F7Z5Y4].^G\,4N['Q<[YG%KFQ-(J0:U
M`<*BNE05+NPNGUIN`#*Y=Y9;-`Y6ZT>.%3[JCV3R9FFY9#S;_)5]K'6.!E%4
M;CDVR2B*AMI122CU&35(A-U0`J9>GOUY@3=9NM^[<H+F?<69$MPXDBWN[B*-
MI!H6M:Q[&T]P*;KO;^V<3:L9%:6CFENE8F$Z>DD$H]LOXPGD48Y3(F01,J[:
MHE$UUW#0Q7!T3HF`P/AH"R*I3%]X#^'5]VEQURN;JW!W%N(!\C&@?K[OQ<Y#
M?]77C5=3&_;#;=X=96?/RG^3'_"LGHYA!VLV0R'?]4'#Q,QB77<&U)%N947"
MJPF?EVD330'J/0-4LD>N=EFGV`W)N/E@=*'_`/D+SZKB*_B]E13T+2VDVP;>
M$FRLR3)K^#'KK]U$4,I9HM:1%ZSR/>Z2Z)Z[5[@DGI0"H[2F;R:KQ"HDZF*=
M(0$-63%UAZW[6N6Y''9[-SW\,GY<U[<O80TTU:^0M-:=H7>#;^TLM;/@EM;6
M/FKJV-@/J(`*D1XK<KI'*$@G8&0!;)WB#-5Q#S;)/RK:X4FJ8B[:.6I1[+.7
M11)O`2!VU2UH!1#KZB^R/[7-WU=N)-A=03%!NSRP87,HWG;2FI;3Q5#N_P!*
M@7J%T_BVU#_5L6XR69-"-3RFO9W<$_8#GZ_$8/QCT\.FO0<M#0`PU`%/>44.
M.K".+@:K[O/^L;^D/Y]:+5?!.:E!,8:B6G[02=0,`@.X:@%*>[KHB858/J`8
MKR)SBRQP=AF[I.\<5V0PN0]V&E6J\+<MP)"U6NRR8U@"17*,S:#"4:K.%#',
M"FY4NT!1'1$_;>?]8W](=$0WF]IQ`/:(F&@![:]?#1%&AR-]2=CQ8F;O_BGQ
M+Y>CCVU)$6`YFM6Q+9N?&DJS)M!*9:RS&\3/8Z,=;Q^)^@V,42T,`#HB;79W
MKV<7,G7#&V;BG"_++)UYRY%E(ZT[+Q?$3$T[(W`!<*%:MKL.8K=ON*"BIJ)D
MW!4P5T1*Y>WJP0V)X@;IS9PHYVXAL5$Z?S"^KBQ!#R,!$)G$-JLLK!WA**1Z
M/ZPJE)M#[1`-$3T^-O,+CKRYMMU<^`<HPM\(1@I$GH5/S45==LK+`&Q"XK8E
M46<Q%B)AVE5,EV%#?<.;1$Y3>?\`6-_2'\^B(FW]D>Q<66I+WUDJ\K?L6S8%
M$R\Q<MT2S6'AV*92[@*J[>*I)F64#HFF43**&^$I1'IHBBUC_5[L++ET2-G<
M,>.?(GF$_AW1FDE==CVXTL3%C)83`4$W>0,@.HAB@GM^(!.W(8P=2E,&B([7
M!S+YZ6E&*SLWZ65_R\.@F+A5O8?)/$MVW.DB4!,;_EMJR;.'ZP$)78@901'H
M`".B)&>/_K?X0S;G:Q^-\UA+/>)<KWQ=1+*1BKZB+<28V]<*C)X[(QGQ),M)
MED<_E!(`"RWB8Q:!M$1T135E.:@?&<?&@B8:B%1ZZ(ON\_ZQOZ0_GT1,SYV<
MU;&X(X(>9NO>)D+MW71;EI6]9<5)-8J6N28FG8>:39.G22Y"HP\&BZ?KF%,]
M2MMG03AHB=-9=WPE^VA:M\VL^3D;9O*W(2Z+?D4%>XF]AYV.;R4<L4P"/4S1
MR01J-=PC6GAHB,V\_P"L;^D/Y]$6S<;;]XW]77Q'Q[M*_AIHBK_Y/BW]P9SR
MJ;MJ/537_<I1*FH/=/V))5ND`)E'N'V-FQ"`!?`"UU\WG6>QR6:Z[;HC89'R
MG<%\SF!+G!@N'@,%20&@4``686WYHK+;5C((F&ME%QK]0:Z%+WC.P(^7!&+D
M2$BYHVPL>]=%%-)9<1HG'2PB!3$(J%2I*B4-IN@]!UDGTGZ78[(6UOB+QIL\
MA4&`O91LAI4ASJ&A+N\%6=G<O-'')*TAS*U(J?"WMY?E3MV..8]@VM5U<2S6
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MP28S"N-WD(ZA[XV&H>-'BO*&D!P(KVC6JDS;V7DFD#W_`#3P!*0[#T8\M_/^
M*]H*-5OK2+04#JF<"N%C-U@,G7<F*J*PE$IJ"(#X:@+H'8W^W?:%VL9HC!=R
M9B"$ZFKXI)&M)=KQ',Z@X=RO#=T\5[M2YC+&\C8G.TKQHI\*4'Q$:!3K]G2H
M_;KZ+G,#7%P^DL/(QYQ-P30U(IV+[K:JR;ERXY"0?%;CAES/$Z9-0M@VC(/H
M2./U4G;N>$".M&`;I!4ZR\O<3INB!2@([3"-*`(Z(J1MW1&>/36YQ\<.0&5W
MTC+7G?#"R^1]ZOB$4;*R#7*#ET3,MD/1.?:\>0Q99VT.`CT$$Q]VB*_3`ST3
M=$)#7+`/$9*"N*(C9Z%D6YA,@^BI=HF_CW:)Z4.FY9KIG+3V&T1=;\/AHB07
ME4R;2'&#D8S=I$<-UL&96*LDLFDJFJ0+&FQV*$,GM.01*'0?=HBJ:?Y;=))3
MEEEM51,IUD^.`@DL(`*J(*WO:9%01.("*8*@F&ZGC3KHBN;RL5&S\:_@YEBT
MDX:89N8R5BWZ";MA(QSY(S9XR?-EP.DY;NVZADSE,`@8#4T14)>(4],<9/5]
MMRS<1NGC>#0Y179@UY$,E53MYW&<K=TK`N(-TW0)V7;&)8H$<)`8M$%6I3EH
M.X1(KYMTW)!V9;MPW=<TBA$6Y:T/*W!/2SL:-XZ(AF3B0D'BYJA1-NT;',/O
MI0.HAHBI3N<@9<]=+G]!8W>SL[:?&"UI&3N=I:L<X4;MK1P_`.FZ#JYG"0`L
MS<Y)OLZR#=-VX(?RBSL")$*1$P"17+L38EQQ@O']NXMQ-:,/9%AVJQ280]OP
MK1)LV(0B8$5=.SE+WI"2>F#N.'*QCKKJB)SF$1T1*(!0+42_"-0&H`0*#T`1
M#X:U&GOT11;\^.#!\TY!XZ<G<*6O#)\D\"YHQA<+B3%\RMT]]8NCKH8C=L!/
MRB^Q!X]A(I55Y'&5JKN(H@4=JH`4BE*$2CU+]T0`2^SX1`!+T$`$.GLT1?*@
M`A[:UZ`8`,(T$2E*`]!$XA3[!T15._6)8Y#YM7KR4'&C]1QB7TT+%MM[=+9L
MV5?MKMR[D&4:.,A,FH)``%>X]QTV*=80$PI]A4@4[AJD3Y?0"Y-AE[B(_P`*
MS;X%[MXVW$:VF:2RI3+JXTN<',Y93@@"85%F\4X\[&;@"A"-4P]VB*=_K[0V
MC[0Z#0?:%0Z=-$6S]'^S_O=$4&\]'H.LY9.%1W'ME`R)<XE%RJ=`0_XR[&N\
M"&,!@I6H`.OG[RF,==^T-NPMN&1N_P#9K_YQ``_ZJ3TK+6(\FT+`MX_HH?\`
MEA/UQ<V[I6S:7EK.N9GM/VV3M?S4N442;RD8O/*(.3K4_0,<Q*![]>C72^PN
M;6QEGO;C'7D%M"9F0>`SN>QFAB<*'3M:#4G6B@_/2RRS!H+VASN0TK0@]I[$
MD>.[W/>4X\N.XES&=O'SL2H*&J6/:)*BBVCD`,8W:09D3`H`%!$>H]1$=0OM
M+?=WNW<4N<W-<DP#(OB$3@:6[>9S&AP'$C2HU(XG@KHS&(BPUC!;63`[E8'<
MW>1K\:=9(W'!1[9@XC3"FX[K=NJDF;X79')RHJH+;>HE4(H(!_\`+[=9=9+=
M.!QSK5F)FY8G.9#(&.H;GFH.6,'6IK2H5D06,]VYTL@`C![M/5VI)\J-3-R/
M&<1,V9`QR7=3\I'NA;21C=JITGSKR*[A14`\2@H`!3W:BKK/9W+('1XV?%6L
M#F5Y&\C9J$<'$^(O'!WVJKM]NW#Q<`.#RX'B>'J'`>\F/6>P3:YYQ@<KMJZ`
MM]P8`9NJ*H#^]I".XQBD,<PB-:TZZ\[MBX\X[VE=I,<Y[W/SMHXEQKK^H:/#
M]G12SD7NEVG>EW'RG?NJ;GVC^/\`GU]`<G`+%2V_(/WBOFJ2JJ#+G9=L%R8Y
MX\6.##RXH=CC'$LDSY5\FQF)=E&1;Q*V%4W&+;%?+OEFR#ES)OCE<JH`8PBB
MZ(H)=H5`B1S_`#`6+<?YGXP6KFBS;KLF:OC`MUI^?:0]RP$A,2&.KX7;PD\T
M;-6T@HNY"*EO(O03(4YB)$5$`\1T1.)]"?DV&=^%L5CV;?\`FKZXYR@8UE06
M,8[IS9ZR:DKCZ2$3G,H=(D,J=AN']-B("-=$4T^B)#^3G_C5R'_[&Y7_`.AI
MS1%3`]"O.T)Q^Y#9-NR>L/+F0&<K@E&%+'8;QY,Y*GXP_P!70+X\G+PD&/G6
MD05)H)?,4$H*"!?:&B*;?*_KUX*6/_"_C?8F0[JSU<<PWL6UF6789OAVQK6N
M^7=%C(AU?TG=<@$E'M(Z1<IF71.W1%4H;3*)@;>!%V/37](*2XXY'?<J.45U
M0N1>1\R_G9V'B8$57EHV#,78X</+@N$T@[215N2\WQWBR1'!2)M&21Q!$IS#
MW-$3C_6HO27LGTW>0B\*LLV=W*VM"R%W"`E!1.,NJ\(:,EB;C"&TCJ..HB:G
M6BFB**O_`"S]GPYF?+B_NT49Q!_BBS$E2D#>A$JMKJN%=)-00$Q$G+X2&'VF
MV`(^`:(K4NB(:(A0!\0KHB&B)M',7D9`\3N-&7<^SYDCDL&TWSR$CU``QYN[
MGQ0C;/A6Y!$!.I(W$[;D,``(@GN-3H.B)E'IO8MQOC;A(SM?-5]V#*9)Y,M+
MMRSR*^9WG;1GTO<F;&R[R6B)(YY(RG<BK:?H,SD'HFJ52@!UT15VO3KR$;T\
M?52E\+7'<+)QCZ[;TGN/$],MWS1:$EHF<E"/,4W=YILLNS,@21^7AW`-\"3Q
M4#"4:AHBO)C4.@^/MK[]$6S]'^S_`+W1%`Q><DU:YPRCYITHD0N0KH$4RI=\
MYREF771/><B1!]U1H'V^&OG:WMD,;A_:#W5+?%Q8[<M^:`_]S(LM[`";:E@P
M\/T47[@3TL27DGO10MJ*BHT$T2KR-RS@>?<,F91`3+J+*=ADU`3U`I")[SF&
MA=PZS\Z.[UQC;N!VWH[:"/E_'N;IWA@;RFI',YHU&FM=2%$NZ,4]A\P24!!`
M:-.9U=.]>.X<(+/YUW>6(;EAV,;<%P.&_P!/W**T>BXF5R$6>NK>=-TW)DFC
MI<XB*"B1>V8:`/4`UT^XN@%S=YJZW[TCRL3++(73_,MKD@,GF-0^:VJ6^$FK
MA0D4-5OM=XNBQT>)SL'Y(\<M#4-X-]9)`'I1[M&QGMM+(7)DVX&;M&,E"L2,
M;<,Y?M8R52`QR.9=PNDT.NW9'(!^R1,U3%`1&@"&I"V5T]O-LQVNY.HU[%<L
MM[@,#8C46TM:![Z$Z`T.JZ3(Y`3/_3X=IY7C2M-0?7\:).7KQ)W'#:XHJ,>*
M')O97%!*C'KR;10H]IR0Z7?:O$SE#J4Q`.0:@8Q>FK0ZW;XM2Z4;IM[-\9YO
M*EMW>)S->1QHXZN;0G3CV!7)MK%D/::N'I:=:'M[Q[Z:!CZ0:.L\XM%J<ZH'
MOR$VBLGVU2`#Q,`(H!3&(8P`%:@(@.L%NE63Q^5]HO:D^-?*^V;N&T;X^+3Y
M[#0:#37WU(^=@%OM>[9V&%Q^`J=CVC^/^?7T.2<`L2K;\@_>*(V3,B6OB/'E
MZY0O5^E&VG8%KS=VW`\54*GVHR"8JOG!""I0@KK]L$TRUJ=0Y2AU'5)55!)Z
M9O$+&?,:P,P<XN8.(+6R;>7*[+ER7E8\=?D4$HE:.,8-TX@+88P:2Y@\HQ=I
MMCIA0``Z#1$0Z#U(I$KA]+/T_IRWIR`:\5L.0+J:A)6);3<1:;1M*PZTBP<,
MDI2/<D-W&[]@=8%$5*U*<H#HBK`^DGDNX>"_J97-QMR2Z&-C;\N"X..]W>:,
M*+4MY04FY<8XGQWG*GMD7K<&R1Q\4I,HUZZ(KO\`[P]H"(#^$.@]/9U^T=$2
M'\G/_&KD/_V-RO\`]#3FB*IA_ELCF+ROR^`"8-W'$@#01KM"_+3.!0"NT?B+
M7K[]$3WO7F]/%O>5IK<UL1VZ"EY6,R;MLYPD2WVJ779C?_!7^5NU)O<S=G'$
MI7RA0%1>.$#B(^7J)$O?HD>HR/)K%B/'3+$TDKG;#T`U)#2C]X51YD_&K,J3
M6/FR*'.)WEPVNF)&D@!0$ZB().1#XCCHBDEY^8!?\GN'F>L*PB22USW59#MU
M9Q%2E$I[QMM=O<=M-]QQ`B0O92+3;[QIM[M?9HBK$?Y>[D#'X@Y/9/X]7RJ-
MMN,X0;9C",I0QV2K7*>-'DH"]K/&K@$O+RSV#?O$0*;XO,,RI%J8U!(KG&B(
M:(BK?%ZVSCBS[GOZ\Y9K!6C9D!+7/<LR]4*FVC(2$9+/Y!XH8Q@W=I!$=I0J
M8YA`H!4=$7,Q;D>W,P8UL3*UG_-"VID:U(2\K:&<C'$-+&A+A8HR,6K(Q+K]
MYCW"K5<AC)'^(E:#UT10I\_WQ>:?/KBIZ=4=LE,8X_>%Y,\IVB9E%6+J&@$#
MJVE94P"0@"8/D%2@8AA#<:61-2I-$4@'_K*]/@0WEX@X+\!-O&S&?W?$3"(5
M,/P^(>WPT15L?7?X/8_XP71@_./'NPH'%^/[I;NK%GHVS&`Q43!9'MUP>?M:
MXB(($.1H[F8155,1`0$RD80?$*Z(K.'`/DJUY:<2L,9H[Z2EP35JH0E^(%5*
MHHRR%:@A`W<W6*0*)&<R;0SLA?8BX3'VZ(GE_H_V?][HB@FY66/,X\S9=SA5
MNN6+NZ66NB#?&*4&[M*64*J]:HKF$""O'2'=`Y*[RE,!J4IKY^_;!Z;9C8'6
MG(W4[S#@\Q<S7@N.71QF>9/*!X`@NIZ=%E7TXS-OFL+'%$6BZMH6QEIUKR#E
MX=]$6K5R0[:LTHSN&0:%42,9L54I^\Y34!,KAZO7>N("/P`8*$#J'OU'NS.J
M=SC(+3"2@MLB>6A)J&UXN/;7CJNQRV$CNN>:,`OKXM.![O0G,1N8$TI&U6B#
ME(K"WW$:1(#'']JY.\3=2KQ0*U%95Q0A1_W:8>_67F/]H"PM\GC+*)X_2V$L
M9;0Z&I`.@T^D59LVUW26TP+:EXUT]'#WOC6IYF(AW5SQR[I$6LZZ?JT$PBFC
M(HO7#N.>5Z@(E/5(0#J8BIO<&N#ENNMC_4\Q9-DYK>]GE?3FJ!X3P'`4HN%:
M[3D%O;N:W4/I6FO'@FV7+DAT[;'CS*@LW!50Z2"@B8S58]`440.7J4%!#XRA
MX^-*ZQ,WCU-R66LW8MTY-H20"X=E=`'<>'>I&Q>#A<2]FA;H?5Q1TXE6-+7[
MFVW)4K=<T-9;OZEF7Y2&!N@+8J@QC%14P!^\.WY2"4OWQ*41I34N^QAT[R.^
M^L5CE(HR,%B'BX?(!IYH)-"?30-74=1<U:X;:$UOS-=?3.+`-*\M!\6JFRFI
M1G!0\K-R'F180T<]EGH-&CA^\\I&ME7K@6;%HBX>/'7:1'MI)$.HH:A2@(B&
MO>T`._$UKP6*9+BQF@IJ3^Q5>?5=YE9[Y>XI5XZ\2>,7)V3QE<CEG)Y0R7+8
M2R);9[E9QCCS;.R("$D(1O(!#KOB).'[I?8*Q4P1(2FX1U12\>GQR;QW?V,<
M6X'B,19IPS>V-<0VY'S%EY%Q#>UHP40%KL8R"D4HR]).&:VS-"\>&!=(J2XK
M*E4,<2U`U")[66LIVQA:PIG)%X-+I?0$$9@F]:V7:-P7S<:II%\WCVX,;:MA
MC(S3\I7#HHJ"DD8$TP$YJ%`1T14D_46M7,G)WFK=O(WB_P`5N3L3;[LEA.V-
MT.L*WW!RLI?5ELVQ#7HWB7$4@O'&458-")]P0.H+7N&ZF`-$5COA5ZEERY78
M6)C/DWQPY"87SO(N8RTG,FZPUD);&EU3"C;LA<A+D)!E:6BE)*(BHLE(;$&R
MAA`%3%$!T1:N?7/EE;6.L\8`Q!@/D=F/,<I;ERXO*G;N%,@DL"-?W+"N(9W-
MGOKY$,3,,(QO("J4K#OE<')L`Q?'1%7J]+"6Y%^GYR(D,CY0X<<FY7'5Y6$X
MQU<[R$P_>KF9M]JI*P\W'S\;'GB-THDV<QADUVY3D5.FJ`E..V@D5R3#>8\?
M<FL</+IMJ!O-"U9!U,6G+0.4L>7)8,NL)$"(RC&2M2\(R->.HU9H][0*E(=N
MN4QBE,(`.B*G%RYX/\EO3WYX0U_\/;`R;=%J%FBY2PU+619]P78V@FCZ0V7'
MC.YBP#1X16-8'548F1<&3,YBUB&"IPZ$5D?B[ZE)LQ+V+9&;.,7)/C[F*Z9%
MI`FBKAPYD"2QRI,+H[4WS6_F\`A'PL2Z.0YMTB1#R]0`YQ$*Z(F5^I;Z-DGE
MF]I+E?PPF"V#R&;2C&[YFR4)%.WH>]+KBWB+Q"\K4GP40)9U_D52[BHG$6,@
MH`&4[:OQB1&;C7ZM%_XQCVN*?4TP;E7`F0[=;M(T,P!C>ZY7'U\F;B*!I>8"
MW(J2;6_*+`4JJKAHJZCW!C;R=L/@`B>G,^K;Z?,;'J.H_D`UO-T!0,C`V)8V
M0[LN-Z<U1*DVB8JTE%174-TH;90PA6FB*$'G;R2Y[>I8W;X'X\<1N0-@\7)F
MY8MK<ER2]CS\-<&2(L\J@@$A=;F2;QC"!LUDD<7AHLAEEEQ3`5U1``(!%.GR
M'Y?6APMLV!Q+9F&\X9KR-;>,H)M8%A8OQ?>$]"2;:*9?((1G-WU&PKRV[?1`
M8D1<%,=1R0E-J0B(:(H./39Y"93P-R9Y49_YM<:.3<7=G(X8R1:Y(B,$Y(N9
ME;:+*4?/7EDEB(V!>R;*",U69IM5$R&(FE')D,4#&"A%;"AY1K,Q,5-LRNB,
M9>-8RK,KUHNP>E:R+1)VV*\8NTT7+%T"*Q>XDJ0ATC5*8`$!#1%`=ZRF=[0S
MAQZR=Q2Q[A'D'E;,$??MKEC'5NX/R*K:5LS]LRR#Q]<+6\3P`0TTDG%*+M4_
M)**D<`Z,`'V@;1%&WZ5W(OEMZ?[NXL<YCX?\G)WCU?T\C<;EY#8EOA:X<;W1
MY,C&2G(>(&),E-1,TU:M_.-2BBL*Z8+)B8:E$BLB?^P7!/T_]1_3O(#Y=_#O
M^)FS_P#/67?F'R3^)W\*OE_R[Z<\[]3_`%5^T^4[/._+/W[;Y3]IHB=;?V.+
M+R9$J0%[032<CNZ*J(+$HY9N*T\RP=)[5V;BG03$,&X.AJATU8>_NFFS.IN&
M=@]X6<=S:GYKJ`21GTL=0T([P1W+M<3F<AA+D7>.?R2CCV@]Q':FA2'I\XJ6
M>JN(ZZ[YCD#C4K4'T4[!'K4"E659E4$I:]*]=8;Y3^W5T:N)W36-_G(3)7FY
MKB%Q![.0BW;R@#2AK[JD>/K-N-L9BEBL=?\`;>/\Y03X#V0E39D"^P$IBF`?
M^""("40,'7R?O#7"A_MT=+X#$YF8S?-$:BL\6OWOP=?@5+_Z]FN4M\FSHX4^
M8_\`B6M;@%8R^_N9`OT=XB(B'R0!`PFW[P'R70P&\-!_;GZ7B5TQS&;+W\]:
MSQ?3!!_D]E31:,ZO9J-C(VPVE&&H\+Z_O+;'>G_BU!VFO*W5?4P@103J-1>1
MD>"QNNT#KM6(.2AOZCL$!'WAKEXS^W/TBM9HWY+(9RXBC((#[B'E('`&EOP]
M:Y$G6/<KX70LBL6M=741OKK_`,1.\L;'MG8WA$K>LN":046D8#F3;EW.'2P%
MIYE\[4W.7CD1Z[U#&,'LH'369^Q^G6R^G.)_H^SK.&UMBT![F#QO(%.9[NUU
M.X#N49Y;)WF7N1<7LA>\:]W'L".0E`1((B-2"`E&O6H4H/XJ:O?A[E`/>7`+
MR01IJB[<MZVQ9K,[ZZ+CBK?:`&\%99^BVWU$2!Y=)53S+HQE*%V)$.-1\-%L
M1C(?>0IRG,8BA"'+4QC`)3`!RG#=U^(!_)HB\#^28QH(G>OF;#S+A-JV4=NF
M[3ONU@'M-6XN#I@X75V=$R"8YJ>`AHBZ?<4#],P?9T'PKTZ@(_Z]$0,<QJ@(
MCU"G01`/R5H/C^/1$`4.'M'PIXC[@]E:5Z?RZ(L0$W7XSC4*=3G_`).O0=$7
M,E):+A&JDC,R<?%,4BB"K^6?-V+4@E`1*!W;I0A0$PCT+7\`!HBP@IV)N2(9
M3D!(HR<-)IBY82+0QO+/4-PI=Y`]"[TCF2&A@\0\!H.B+K&$QPH8QJ;1*(5Z
M"!O'<4:E-T]X:(L:=*?Z#[Q'WB(]1]XZ(L%D4G"8HN$TUT##U062351$*4VB
MFH4Q1+^&NB+GM8.$8J]]C"P[%QN$_F&D6P;K":M=W<2;E-NJ'CXZ(NJ8PG^]
MU\*`(`(!00,6@#[C``U\:Z(O@"8/NG,`;A-M`0`*B(#X4_6`1^T1&M=$7TQC
MF$![APV@8``IJ!\04$3!3XA`/"OAHB%??\7O`W6H>`@-?&H:(LBG,4``!&@5
M\1$?'V=?``]E/#1%B!C@-14.(_:;I^"@``:(MV\VWQ'[F[Q'Q[M/?HBU'^^;
M_:-_..B+'\=-;',YNVGJK^U;@ZG8"AU]X_EUIY(^M\'RK=YGV0AU_6'\NM/)
M'UO@^5/,^R$/].OCK01-;]'F]T_(N*?.KI2B&JC0`-&AON:JHWFIX^*'L$?8
M`5'[`#Q'\0=?P:W+<F#<@+@LZZ,]X[M:X0;?(<4M#7W=;E&/4DI=_*O-GTS:
M,>S9MW4E).G:J15?*($,I0V\0`I1'1$[C&N3[4RS;RMSVBL_/'HRCR'<I2C!
M6,?M9!D9,JS9=DJ8ZB1@[I=H#\0A[-$267U<."LE9#LS%5U-'ET7*PE'-RV\
M9DA*!"1\O`D5.X%S,,G#=HN=N+<2*)553*H4"GVCHB6F\[YM:P(-:X[NEV\1
M&)JI-TSG*HJY>OG)MC6.C62)#N7\@Z4':FDD4QA'W!UT1<FTLE6]=\M*V\U0
MF(:XX5A%RLC;]QQY8N51BYE,ZD;(`B5PY3.W7V"40W]Q(]"G*4=$2;<ALV'Q
M5:J*%K#&2N2+AE8B'M2V7)3OW#I20=D35>GBV:Z3M1%!$#=L!,3>KM"M!KHB
M-N-\PVY?\C+VF4DQ$WU:3./4NJW+@AEH*0;"Z23`9)LT67<@>+<.1'MF!0P@
M!@\?'1$CO,]^W=X[M['A"QQY7)5X1,$T7?BU`(F.;+%<S4TFHY*8&P,FH!O5
M`2[4S&J-*Z(C_CS,N+7,Y`8?M<9UJ\9VPB>US2-N2$1$7!!PS<&PO8%X]30\
M\W$C8Q@.!"D4H(E$:A4B720D&,4S7D9)VV8,&J)W#IZ\63;-6R"=.XLX67,F
M1%(E>IC"`?R:(DF:9VL63OZW\<1`7%)7!<$>^F$#DMY_'QK*&9(G/\X=NI5!
MB*D<\,0R:*J150.;P]@B1=')F9K%Q+'I2%W/)`.\=$",8B-<2L@5)PY29HNW
M*"%",6:KM8B1%%SIE44,!2;C=-$7AM[.N/;JOL^/()U,/9HL4XETWP0;]*WG
M+=F"`O$FDXL0C1PNT,X*13;5,JH&)OW@(:(M^0<W8^QD^AHRZ9%Z1]-RK*(1
M0CHY>0!@X?[Q:J3"R0E0C$54TSJ`"A@4,D0R@$$A1-HBX:?)#%1[K<V>>3EV
M\DC%*3+1TZM^30BYQDFLFV3^G79T@/-K/')Q3;%03,+DY3`GNIHB-6,\M6EE
MEK<#JU0F4AMB;4M^::3L0O#OFDFDD"QD3MES&.`@0>H&VG*/0Q0Z5(C=/W/!
M6NU3>3K]-DDNX*T9I;5EGD@[.%2,XUBT(J_?NS`%0313.>@5$`+UT1$NP\OV
MGDR=O&`MEO<"A;*<-&<U+2,.YBH\DHX*L)XIL#X$'OGV(H&!=,Z1!(/6H@("
M)$J?XZ_;[_M_'HBV?H_V?][HBQ/]\W^T;^<=$6.B(:(AHB&B(:(O)(/$XY@^
MD%BF428,G;Y1,@&,=0C1NHX.0I2E.8QCD3$*``B/AHBCFP7<4$,==F:T4F]]
M9URS/3B=I6C%N0?R-O,R.%6,6W?)[SEMJ/1(@4T@\<"EVVR14RU$=HD3P,2V
M`EB/&Y8N6D"/I0Z\M>-[RY1.*#J<DE#2$^N@0H=SR;=,#))`/4R:0"%!T1-[
MXRR,5D._+RR\$:<XR8/K;L5FU9I!$V-8<*Y!%NV66`B*+.>NUVH=R9%,3JG3
MJ=6@FT1&'(Q"2G*>P`O5XVC+"L+'$U?<0I,+)-X=Q<B;PS)9Z3OG*@L_ADU4
ME!`P"8A"`(!U$=$7IP6RF;\ROE//SYF\C+:N)M'65CU)X@NU=RUMP9TRJW"J
MV.1-5)I(N$P,B:@%.0QC`(AHB+ET3%OWERXA8R5DHB/MW!]J.;KE'$@Y:LRO
M[MD2-R-`<.5!2!4T*T624VF$XDH;:`==$1JP=`O[NRYE;/[IHY8P=UD9VA8*
M3MNNU<2MMP96J:]RJMEB)F19R2S,H-Z@/<2J</8(D2>WRK:%]\AY:Z,@RS")
MQ5QZC(>(>KR:JA8A]?5RJ^;*T=4`2F09G,F"@"&TPI@41`*Z(E8MBWR9%SX\
MS(B;=95F6:2P[)>HE`&T]*OU5'MPS44?M@92%8)+^405*(IK*[Q)4I0$2(FW
MKE6VYK.5PV?=SE9>W\2PD=-QECM4'#I[?]\2"0O".SQX(F2?L;7:`4405_=T
ME3BNJ($3J!%SN*UQ*Y+N^_LPSJ*SJY+Q66C(PC8GF(BQK*@G0-XV`5DP`K<\
ME+NCBH)$P%4Y$>X<I"F"I%OY&0O\6<L8WPA$D%!NXV7YDV5:("#E*VH4ZC:#
M9KO*4!1RX47\L0YA`%52B`5`1T1/.CXN-B&3*.BF+=DRC6:;&/;MTDT@;-$B
M%*1NE4*%)\`"8*T,8-P]>NB)B-Q1%OYLSA<4O-^4;X4X_*.)&YE@3!NRN_(I
M6A7,DH\5`"IOD(-DS(@L)A-\"/:#X51#1$GB,R>&MV^.85WL2!<5UJEM3`5M
M.RB5O;D6Z%2)MV4%N(II-3>73,OU``0234.&T3U`B=[QMMMA9V+&C1(KQ=VL
M\>S-R7&]1,D:Z)Q_1[-3[,5OWQS$E<J&0:JJE+WDT!.2J9BF,1-;2Y'PY+1R
M+G/9]29#++2ML69;IT3#&XQM9-\2+BU7ZAR^79.YMT;SBZG^+?*&*D3]B00`
MB<QQ;A6T)C%(H>9?RTS(N+ANFY7!`\O<UR3@`^E'$8X$0.^C8TR@,BK`4$CF
M1-VQ,7XA(G'Z(MGZ/]G_`'NB+X</B-X?>'VA[Q^W1%C0?L_*'Y]$0H/V?E#\
M^B(4'[/RA^?1$*#]GY0_/HB%!^S\H?GT18F*`TW&```0'Q+UI41"HC0*AX^/
M31$5;8^B>[)C9OT@+@5ZS'TP,,"GF=PU^8!%@)P7`WCWA$1&NB(T+`GVE>_V
MNQVE._W12[?8V&[N_N52!/97=N#;MK71%RX#Y",4V^F?D@0M5`;?3PL0BMV\
M>[Y?Y?\`NF_?7?M_2\=$7,N4+.[+`;R^EO+>8$6!;F/#^7%V!BA1D,H42BN`
M;=W;$!,--$7IN.:4@(5>49PDI<2J*5&$1;K=NY<O!.B<6Y0(X<M&R37<4`W&
M4*0I1K71$SSC4WM).$R$[RH2UD,C362Y&;N]A<[ZUGAX>3>&$(*(144?R)$'
M+-D0=B0]M0M1^&G71$^0H%VD$FP4]A!3V"4""G0-FP`$2@3;X4^&GATT1%UZ
M-GA&S'S?Z6&,\Q_S$+\L0,:+OX*?.0<"1MYK[G]?\7A]FB+NM?*BV;"R\KY#
ML)>2\IV09^4V!V/+`B84?+]JFW9\.WPZ:(N$4MIA.O\`::W?J7Y<0)2IHDT[
M\M*3X//B!0D?("D-:J?`)>GAHB]4"%OC&(?3/R,(<%G':^0^0&,%41-YCM?+
M3%9BJ(UWA03%'Q&NB+UE".^:*[?EWS@6Q`5$@MOF8,1,;8)@_P`9V*_=W")`
M&M*==$7NH(^'3V`&_<-/`.H"!AJ&B+B)%@/(R((_)/E8*N?FPI&9`S!>@`\^
M;"FH#918"_UO=`!'IN\-$7CE/I+Y4R&X`M<(7S+((_YN>)-$"XJ/RX6(//W,
MKD`_J=@"<?T=$1DH;X!`2]N@_"44]HDVB)-ANA@`P4\/A`H>'71$2P#''R61
M$@V1].>=+\W`#6_\B"4%8E0D0*7R`O?,;:=W]H!Z4H.B(Y(%2[*/ES("V[*?
KENQL!+R^T.UVNV()"CM^[L``IHBVT'[/RA^?1%LI\/L_J_>'^]_#HB__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
